Texas Breast Center, led by renowned breast surgeon Dr. Valerie Gorman, is pleased to announce the use of Agendia, a global leader in genomic testing. This collaboration aims to provide patients with the most comprehensive and personalized treatment plans available, minimizing under- and over-treatment, and improving their quality of life. As part of this partnership, Texas Breast Center utilizes Agendia’s cutting-edge genomic testing platforms to provide actionable insights throughout a patient’s breast cancer journey, from diagnosis to remission and beyond.
Breast cancer remains one of the most common cancers affecting women worldwide. Despite advances in treatment, there remains a significant gap in personalized care that takes into account the unique genomic makeup of each tumor. Agendia’s genomic testing platforms, including Mammaprint, which is now included in the National Comprehensive Cancer Network (NCCN) guidelines, help match each patient to the right treatment at the right time, shedding light on complex treatment decisions and leading to the most relevant and targeted approach for each individual patient.
NCCN recommends Agendia’s Mammaprint as an assay for consideration of adjuvant systemic therapy. Mammaprint can help determine a patient’s breast cancer recurrence risk based on a 70-gene prognostic test. If the test finds that a patient is considered UltraLow Risk, they may be able to avoid certain harsher treatments. Dr. Gorman always wants to help her patients find the best possible treatments options available for their health needs.
“Personalized medicine is the future of cancer treatment, and we are thrilled to partner with Agendia to bring this innovative approach to our patients,” said Dr. Valerie Gorman, Chief of Surgery at Baylor Scott & White Medical Center – Waxahachie. “By understanding the unique genomic makeup of each tumor, we can create a treatment plan as early as the first patient meeting, providing clarity and confidence on the path to recovery.”
Agendia’s tests are trusted by leading physicians and institutions around the world, providing actionable insights that help doctors achieve the best possible outcomes for their patients. This partnership between Texas Breast Center and Agendia underscores a shared commitment to improving breast cancer care through personalized medicine. By leveraging the power of genomic testing, Texas Breast Center can provide patients with a clear and confident path to recovery, improving overall quality of life and minimizing the risk of over-treatment or under-treatment.
In this new era of personalized medicine, the partnership between Texas Breast Center and Agendia is a significant step towards revolutionizing breast cancer care. Dr. Gorman and her team at Texas Breast Center are deeply committed to providing the highest level of care to their patients, and this collaboration with Agendia further enhances their ability to offer the most precise and personalized treatment plans. With a shared vision of improving patient outcomes and quality of life, Texas Breast Center and Agendia are excited to embark on this journey together, contributing to a brighter future for those affected by breast cancer.
About Texas Breast Center:
Texas Breast Center, located in Waxahachie, Texas, is dedicated to providing comprehensive breast cancer care, from diagnosis to treatment and beyond. Led by Dr. Valerie Gorman, a board-certified breast surgeon who specializes in surgical oncology and surgical diseases of the breast, with over 20 years of experience, the center offers a range of services including breast cancer surgery, breast reconstruction, and ongoing surveillance and monitoring. Dr. Gorman and her team are committed to providing personalized care that addresses the unique needs of each patient, utilizing the latest advances in surgical techniques and technology to achieve the best possible outcomes. Her targeted approach to breast cancer care matched with her unparalleled compassion help patients feel reassured and hopeful during a challenging season of their life.
See original post via Press Advantage News.
